Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Phase 1- Dose Level 1	5
Overall Study	STARTED	Phase I - Dose Level 2	9
Overall Study	STARTED	Phase Ib Expansion	20
Overall Study	STARTED	Arm A: Pembrolizumab	40
Overall Study	STARTED	Arm B: Pembrolizumab Plus Vorinostat	46
Overall Study	COMPLETED	Phase 1- Dose Level 1	4
Overall Study	COMPLETED	Phase I - Dose Level 2	9
Overall Study	COMPLETED	Phase Ib Expansion	20
Overall Study	COMPLETED	Arm A: Pembrolizumab	40
Overall Study	COMPLETED	Arm B: Pembrolizumab Plus Vorinostat	43
Overall Study	NOT COMPLETED	Phase 1- Dose Level 1	1
Overall Study	NOT COMPLETED	Phase I - Dose Level 2	0
Overall Study	NOT COMPLETED	Phase Ib Expansion	0
Overall Study	NOT COMPLETED	Arm A: Pembrolizumab	0
Overall Study	NOT COMPLETED	Arm B: Pembrolizumab Plus Vorinostat	3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02638090/flow